XRCC1 and ovarian cancer: Since mutations in TP53 and BRCA1 were not predictive of sensitivity to VE-821, we investigated whether expression of 13 key proteins (DNA-PKcs, Ku80, Ku70, ATR, CHK1, PARP1, XRCC1, ARID1A, RAD51, TopBP1, Cyclin E, APOBEC3B and ATM) (Figure 2a), previously identified as determinants of sensitivity to ATRi, would associate with the sensitivity of the panel of ovarian cancer cell lines to VE-821.